TUESDAY, SEPTEMBER 19, 2017

Scientists develop reprogrammed E. coli to treat resistant infections

E. coli Read More »

Canadian researchers develop new TB vaccine

Tuberculosis Read More »

Measles cases drop fourth straight month in U.K.

Measles Read More »

U.K. PHE advocates malaria vaccinations for travelers

Malaria Read More »

Children with egg allergies can safely receive flu shots

Flu vaccine Read More »

Meijer pharmacies anticipate 40 percent more flu shots this season

Meijer, a Grand Rapids, Michigan-based retailer said on Thursday that its pharmacists anticipate administering 40 percent more flu shots this season in comparison to last season. Read More »

Possible new approach to fight TB discovered

Tuberculosis Read More »

Senegal commits to free health care for children five years old and younger

As part of its "A Promise Renewed" initiative, Senegal announced on October 1 a commitment to make health care services free for children under five to try to decrease the child mortality rate. Read More »

Researchers discover key mechanism behind herpes infection

herpes virus Read More »

Six more cases of MERS-CoV reported in Saudi Arabia

MERS CoV Read More »

GeoVax receives patent allowance notice for DNA/MVA vaccine for HIV/AIDS

GeoVax Labs, Inc., announced on Monday that it has received a notice of patent allowance from the U.S. Patent and Trademark Office for its DNA/MVA vaccine. Read More »

CAES reports WNV and EEE-carrying mosquitoes in Connecticut

Mosquito Read More »

Social inequality has major impact on European infectious disease burden

The financial crisis may have widened health inequalities in many Member States, according to a report released on Monday by the European Centre for Disease Prevention and Control. Read More »

Scientists identify molecules that block flu virus replication

Influenza Read More »

Scientists discover new molecules that have potential to fight the flu

Influenza Read More »

Valneva licenses EB66 technology to IAVI to develop HIV vaccine

Valneva SE, a biotechnology company based in Europe, announced on October 2 that it licensed the use of its EB66 technology to the International AIDS Vaccine Initiative to research and develop a preventative HIV vaccine. Read More »

Fecal transplant pill may stop recurrent C. difficile infection

Clostridium difficile Read More »

Malaria vaccine shows reduction of disease in Phase III study

GlaxoSmithKline, a research-based pharmaceutical company, announced on Tuesday that its malaria vaccine candidate showed continued protection of young children and infants from clinical malaria up to 18 months following vaccination. Read More »

Phase 2 trial of Novavax RSV vaccine candidate begins

Novavax announced on Monday that it has begun enrollment for its Phase 2 clinical trial of its respiratory syncytial virus vaccine candidate. Read More »

ARC successfully completes Phase I trial of hepatitis B drug ARC-520

Arrowhead Research Corporation announced on Wednesday that it successfully completed enrollment in a Phase I clinical trial of its RNAi-based candidate drug, ARC-520, against chronic hepatitis B virus infection. Read More »